Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 ◽
Vol 15
(2)
◽
pp. 213-222
◽
Keyword(s):
Phase 3
◽
Keyword(s):
Keyword(s):
2016 ◽
Vol 11
(4)
◽
pp. S117-S118
◽
Keyword(s):